AA
KYMR icon

AlphaCentric Advisors’s Kymera Therapeutics KYMR Stock Holding History

AlphaCentric Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Buy
5,385
+43
+0.8% +$3.69K 0.52% 67
2026
Q1 		$445K Buy
5,342
+307
+6% +$24.3K 0.44% 81
2025
Q4 		$392K Buy
+5,035
New +$340K 0.39% 86

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

AlphaCentric Advisors's KYMR Position: Q2 2026 in Review

AlphaCentric Advisors increased its Kymera Therapeutics (KYMR) stake by 0.8% in Q2 2026, buying an estimated $3.69K and bringing the position to 5,385 shares worth $617K. The position accounts for 0.52% of the portfolio, ranked #67.

AlphaCentric Advisors first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • AlphaCentric Advisors held 5,385 shares of Kymera Therapeutics worth $617K as of Q2 2026.
  • AlphaCentric Advisors bought 43 Kymera Therapeutics shares in Q2 2026, an estimated $3.69K.
  • Kymera Therapeutics made up 0.52% of AlphaCentric Advisors's portfolio in Q2 2026, its #67 holding.
  • AlphaCentric Advisors first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.